The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
This article briefly reviews the history of pharmacotherapy for obesity before focusing on the clinical trial evidence for the use of the GLP-1 agonist liraglutide as a weight loss agent and comparing its efficacy with other emerging drug therapies for obesity.
Source: Therapeutic Advances in Chronic Disease - Category: Internal Medicine Authors: Crane, J., McGowan, B. Tags: Reviews Source Type: research
More News: Bariatric Surgery | Clinical Trials | Eating Disorders & Weight Management | Epidemics | Epidemiology | Internal Medicine | Nutrition | Obesity | Sports Medicine | Victoza | Weight Loss